Class summary at a glance.

Every drug in the Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 3tracked in Part D
CY24 Part D spend: $65.1Mcombined across class
Total Rx claims: 3.2M1.3M unique beneficiaries
Generic mfrs (active): 39across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Acyclovir

Brand: Acyclovir suspension · 3.0M Part D claims (CY24) · 1.2M beneficiaries · First FDA approval: 1982-03-29

34 generic mfrs 380 plans require PA

Low NADAC$0.077

→

Avg plan cost$0.887

Part D spend $55.7M 12× spread, current vs floor

Class share

86%

of class CY24 spend

View profile →

Famciclovir

182K Part D claims (CY24) · 93K beneficiaries · First FDA approval: 2007-09-05

5 generic mfrs 0 plans require PA

Low NADAC$0.270

→

Avg plan cost$0.501

Part D spend $9.4M 2× spread, current vs floor

Class share

14%

of class CY24 spend

View profile →

Acyclovir and Hydrocortisone

Brand: Xerese · — Part D claims (CY24) · First FDA approval: 2009-07-31

Brand-only (no generics) 0 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.